IP Watchdog

NOVEMBER 6, 2023

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. The Federal Circuit remanded the case for further consideration of extrinsic evidence from chemistry textbooks to determine the proper meaning of the claim term “a pH of 13 or higher.”

Evidence 105

Evidence Pharmaceuticals Construction Litigation 105

Complex Discovery

JUNE 17, 2024

states over talcum powder litigation marks a pivotal moment in consumer protection and corporate accountability. This case highlights critical issues surrounding product safety, transparency, and the ethical responsibilities of corporations, especially within the pharmaceutical industry. This multi-state settlement involves 43 U.S.

Litigation 111

Litigation Pharmaceuticals Manufacturing Evidence 111

IP Watchdog

AUGUST 31, 2021

District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc.’s In each of these opinions, the court noted the absence of survey evidence (or, in the Vital Pharmaceuticals case, the inadequacy of an “almost comically flawed” survey). On August 3, 2021, the U.S. On June 7, 2021, the U.S.

Case Law 126

Case Law Pharmaceuticals Evidence Litigation 126

IP Watchdog

JULY 13, 2023

Novartis is currently involved in a multi-district patent litigation campaign to block generic entrants for Entresto®, which is Novartis’ blockbuster heart medication. On July 7, 2023, the district court invalidated the patent for lack of written description despite rejecting an enablement defense based upon the same evidence.

Technology 52

Technology Pharmaceuticals Construction Evidence 52

IP Watchdog

JANUARY 8, 2024

The FCA claim was brought by patent attorney Zachary Silbersher against Valeant Pharmaceuticals, predecessor to Canadian drugmaker Bausch Health.

Pharmaceuticals 59

Pharmaceuticals Evidence Litigation 59

CaseFox

NOVEMBER 27, 2023

Over time, legal frameworks developed to address these concerns, forming the foundation for contemporary exposure litigation. High-profile incidents, such as Love Canal and asbestos-related diseases, prompted regulatory changes and a surge in environmental and occupational health litigation.

Litigation 52

Litigation Pharmaceuticals Expert Testimony Evidence 52

IP Watchdog

AUGUST 26, 2021

The CAFC found that the jury’s verdict with respect to written description was not supported by substantial evidence. Court of Appeals for the Federal Circuit (CAFC) today reversed a jury verdict for Juno Therapeutics and Sloan Kettering Institute for Cancer Research (Juno), wiping out a $1.2 billion judgment for the entities.

Trial Brief 122

Trial Brief Evidence Technology Pharmaceuticals 122